This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for Apr 21, 2021
by Zacks Equity Research
U.S. stock markets closed lower on Tuesday as concerns over the rising COVID-19 cases globally led to weakness in reopening stocks with the U.S. State Department also set to issue international travel warnings
Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.
Abbott (ABT) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of -0.75% and -3.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Walgreens (WBA) Inks Deal to Expand COVID-19 Testing Access
by Zacks Equity Research
Walgreens' (WBA) recent deal with Abbott is part of its ongoing efforts to offer greater testing access, helping reduce the spread of COVID-19 and improve the health of communities.
5 MedTech Outperformers With Nearly 40% or More Gain in 2021
by Debanjana Dey
Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.
The Zacks Analyst Blog Highlights: Abbott, Salesforce, BHP Group, Danaher and Zoom Video
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Salesforce, BHP Group, Danaher and Zoom Video
Top Stock Reports for Abbott, salesforce & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), salesforce.com (CRM), and BHP Group (BHP).
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $123.01 in the latest trading session, marking a +1.63% move from the prior day.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Demand for Nutrition Line to Drive Abbott (ABT) Q1 Earnings
by Zacks Equity Research
Two additional regulatory approvals in Europe are expected to have widened Abbott's (ABT) global Panbio customer base through Q1, contributing to the top line.
Abbott (ABT) Gets Europe Nod for TriClip G4 to Treat TR
by Zacks Equity Research
Per Abbott's (ABT) TRILUMINATE CE Mark study, the latest version shows sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status.
Zacks Market Edge Highlights: Facebook, Sony, Apple, Canada Goose and Abbott
by Zacks Equity Research
Zacks Market Edge Highlights: Facebook, Sony, Apple, Canada Goose and Abbott
How Many Stocks Should You Own?
by Tracey Ryniec
If you're going to buy individual stocks, why not buy your best ideas? Tracey explores what is the optimum number and how to find them.
Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod
by Zacks Equity Research
The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.
Here's Why You Should Retain Abbott Laboratories (ABT) Stock
by Zacks Equity Research
Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.
Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use
by Zacks Equity Research
According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $118.94, moving -0.75% from the previous trading session.
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction for solid product portfolio and improving margins. However, forex is a woe
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
Cardinal Health (CAH) Hits New 52-week High: What's Driving It?
by Zacks Equity Research
Cardinal Health (CAH) is witnessing an uptrend in its stock price, prompted by robust performance in both Pharmaceutical and Medical segments during the fiscal second quarter.
Why You Should Retain Varian (VAR) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on the Varian (VAR) stock, courtesy of its solid prospects.
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
MedTech to Gain From Economic Stimulus Bill: 3 Stocks to Buy
by Trina Mukherjee
Grab these three top stocks - ABT, HOLX and BIO - that continue to show tremendous promise and stand to benefit from the historic stimulus package.